Alector (ALEC) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alector (ALEC) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 34.4% versus a loss of 60.0%. Lexeo Therapeutics is the larger company by market cap ($262.7 million vs $231.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | LXEO |
|---|---|---|
| Share price | $2.08 | $3.20 |
| Market cap | $231.69M | $262.68M |
| 1-day change | +2.72% | -0.31% |
| YTD return | +29.49% | -67.67% |
| 1-year return | -34.42% | -60.02% |
| 5-year return | -91.33% | — |
| EPS (TTM) | $-1.09 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $10.99 |
| 52-week low | $1.09 | $2.98 |
| Distance from 52-week high | -38.97% | -70.88% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +59.04% | +534.38% |
| Average volume | 2.86M | 1.20M |
| Shares outstanding | 111.66M | 82.09M |
| Employees | 103 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed LXEO by 25.6 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
ALEC vs LXEO FAQ
Which is bigger, Alector or Lexeo Therapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $262.68M compared with $231.69M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or LXEO?
ALEC returned -34.42% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.